Search

Displaying results 5371 - 5380 of 7180 in total
  1. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.

  2. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)

  3. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.

  4. Drug

    Telazorlimab

    go.drugbank.com/drugs/DB16374
    Investigational

    Telazorlimab is under investigation in clinical trial NCT03568162 (Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis).

  5. Drug

    Pegmusirudin

    go.drugbank.com/drugs/DB19220
    Investigational

    Pegmusirudin is under investigation in clinical trial NCT00074620 (A Clinical Study to Assess the Safety of Peg-hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis).

  6. Drug

    Duvakitug

    go.drugbank.com/drugs/DB19444
    Investigational

    Duvakitug is under investigation in clinical trial NCT05668013 (A Study to Evaluate the Long-term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease).

  7. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

  8. Drug

    TMC-310911

    go.drugbank.com/drugs/DB15623
    Investigational

    TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available [darunavir]. … TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, making it a potentially desirable therapy for

  9. Drug

    Aluminum oxide

    go.drugbank.com/drugs/DB11342
    ApprovedWithdrawn

    It is considered an indirect additive used in food contact substances by the FDA.

  10. Drug

    Sifalimumab

    go.drugbank.com/drugs/DB12773
    Investigational

    Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.